Researchers at the 47th Society of Critical Care Medicine reported this week that Hill-Rom‘s (NYSE:HRC) Metaneb System may help reduce the incidence of post-operative pulmonary complications in high-risk patients.
A 419-patient study found that patients using the Metaneb System combined with standard respiratory therapy spent 1.6 fewer days in the hospital on average compared to the group receiving standard respiratory therapy alone.
Get the full story at our sister site, Drug Delivery Business News.
The post Study: Hill-Rom’s Metaneb System lowers risk of post-operative pulmonary complications appeared first on MassDevice.